Rapid relief of symptoms associated with allergic rhinitis eg, sneezing, nasal discharge & itching, congestion/stuffiness, ocular itching, tearing & redness. Relief of symptoms associated with chronic idiopathic urticaria eg, itching, size & number of hives.
List of products by brand Merck Sharp & Dohme
Endocrine system
Glibenclamide + Metformin - Glucovance 500/2.5mg - 1 box
Merck Sharp & Dohme
P06002299
2nd-line therapy when diet, exercise & initial treatment with sulfonylureas or metformin results in inadequate glycaemic control in patients with type 2 diabetes.
Endocrine system
Glibenclamide + Metformin - Glucovance 500/5mg - 1 box
Merck Sharp & Dohme
P06002300
2nd-line therapy when diet, exercise & initial treatment with sulfonylureas or metformin results in inadequate glycaemic control in patients with type 2 diabetes.
Monotherapy or in combination with other oral antidiabetic agents or with insulin for type 2 DM in adults when dietary management & exercise alone does not result in adequate glycaemic control. In children >10 years & adolescents, may be used as monotherapy or in combination with insulin. Reduction of diabetic complications in overweight type 2...
Monotherapy or in combination with other oral antidiabetic agents or with insulin for type 2 DM in adults when dietary management & exercise alone does not result in adequate glycaemic control. In children >10 years & adolescents, may be used as monotherapy or in combination with insulin. Reduction of diabetic complications in overweight type 2...
Monotherapy or in combination with other oral antidiabetic agents or with insulin for type 2 DM in adults when dietary management & exercise alone does not result in adequate glycaemic control. In children >10 years & adolescents, may be used as monotherapy or in combination with insulin. Reduction of diabetic complications in overweight type 2...
Reduction in risk or delay of onset of type 2 DM in adults, overweight patients with impaired glucose & fasting tolerance &/or increased HbA1c who are at high risk for developing overweight type 2 DM & still progressing towards type 2 DM despite implementing intensive lifestyle change for 3-6 months.
Monotherapy or in combination with other...
Reduction in risk or delay of onset of type 2 DM in adults, overweight patients with impaired glucose & fasting tolerance and/or increased HbA1c who are at high risk for developing overweight type 2 DM & still progressing towards type 2 DM despite implementing intensive lifestyle change for 3-6 months. Monotherapy or in combination with other oral...
Reduction in risk or delay of onset of type 2 DM in adults, overweight patients with impaired glucose & fasting tolerance and/or increased HbA1c who are at high risk for developing overweight type 2 DM & still progressing towards type 2 DM despite implementing intensive lifestyle change for 3-6 months. Monotherapy or in combination with other oral...
In CHD, to reduce risk of death, coronary death & non-fatal MI, reduce risk for undergoing myocardial revascularisation procedures & slow progression of coronary atherosclerosis, reduce development of new lesions & new total occlusions. Adjunct to diet in patients with primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia...
In CHD, to reduce risk of death, coronary death & non-fatal MI, reduce risk for undergoing myocardial revascularisation procedures & slow progression of coronary atherosclerosis, reduce development of new lesions & new total occlusions. Adjunct to diet in patients with primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia...
In CHD, to reduce risk of death, coronary death & non-fatal MI, reduce risk for undergoing myocardial revascularisation procedures & slow progression of coronary atherosclerosis, reduce development of new lesions & new total occlusions. Adjunct to diet in patients with primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia...
Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to diet & exercise to improve glycemic control in type 2 DM inadequately controlled on metformin or sitagliptin alone, or combination sitagliptin & metformin, or triple combination sitagliptin, metformin or sulfonylurea, or max tolerated dose of...
Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to diet & exercise to improve glycemic control in type 2 DM inadequately controlled on metformin or sitagliptin alone, or combination sitagliptin & metformin, or triple combination sitagliptin, metformin or sulfonylurea, or max tolerated dose of...
Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to diet & exercise to improve glycemic control in type 2 DM inadequately controlled on metformin or sitagliptin alone, or combination sitagliptin & metformin, or triple combination sitagliptin, metformin or sulfonylurea, or max tolerated dose of...
Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to diet & exercise to improve glycemic control in type 2 DM inadequately controlled on metformin or sitagliptin alone, or combination sitagliptin & metformin, or triple combination with sulfonylurea, or max tolerated dose of metformin &...
Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to diet & exercise to improve glycemic control in type 2 DM inadequately controlled on metformin or sitagliptin alone, or combination sitagliptin & metformin, or triple combination with sulfonylurea, or max tolerated dose of metformin &...
Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to diet & exercise to improve glycemic control in type 2 DM inadequately controlled on metformin or sitagliptin alone, or combination sitagliptin & metformin, or triple combination with sulfonylurea, or max tolerated dose of metformin &...